Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is expected to see significant growth potential in the future as they focus on developing gene therapies for various neuromuscular and cardiac diseases. With promising clinical data, regulatory support, and a strong cash position, the company has a positive outlook for their future prospects. However, they do face certain limitations and safety concerns with their current treatments, which may impact their revenue generation in the short term.

Bears say

Solid Biosciences is a life sciences company with a diversified portfolio and promising therapies in development for neuromuscular and cardiac diseases. However, its current emphasis on gene therapy may limit its potential market and likelihood of receiving FDA approval. The company's current assets, including SGT-003 and SGT-212, may not effectively address the unmet needs in their respective fields and face competition from other established front-runners and treatment methods. The risks to the company's success include potential safety and regulatory issues, as well as the financial pressures of pricing and commercialization. Overall, the company's potential for success may be limited, warranting a negative outlook.

Solid Biosciences (SLDB) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 11 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.